Journal
BIOMATERIALS
Volume 28, Issue 36, Pages 5401-5406Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2007.09.008
Keywords
muscle; stem cell; gene therapy; bone tissue engineering; cartilage tissue engineering
Funding
- NIAMS NIH HHS [R01 AR049684-03, U54 AR050733-057497, R01 AR049684-05, R01 AR049684-04, R01 AR049684-01, R01 AR049684, R01 AR049684-04S1, R01 AR049684-02, U54 AR050733, U54 AR050733-010003] Funding Source: Medline
- NIDCR NIH HHS [R01 DE013420-01A2, R01 DE013420-04, R01 DE013420-05, R01 DE013420-03, R01 DE013420-07, R01 DE013420-02, R01 DE013420-06, R01 DE013420] Funding Source: Medline
Ask authors/readers for more resources
Skeletal muscle has been recognized as an essential source of progenitor or satellite cells, which are primarily responsible for muscle regeneration. Recently, muscle has also been identified as a valuable source of postnatal stem cells that appear to be distinct from satellite cells and possess the ability to differentiate into other cell lineages. These cells, named muscle-derived stem cells, possess a high myogenic capacity and effectively regenerate both skeletal and cardiac muscle. Remarkably, when genetically modified ex vivo to express growth factors, these cells can differentiate into osteogenic and chondrogenic lineages and have been shown to promote the repair of bone and cartilage. Muscle stem cell-based regenerative therapy and tissue engineering using ex vivo gene therapy, are promising approaches for the treatment of various musculoskeletal, cardiovascular, and urological disorders. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available